128 results
Patients are reporting lingering symptoms after acute COVID-19. Read about post-acute COVID-19 syndrome (PACS) also known as long COVID.
EBSCO Chief Medical Knowledge Officer and DynaMed® Founder Dr. Brian Alper launches an innovative effort to uncover scientific knowledge related to COVID-19.
Molnupiravir is a new antiviral pill to treat COVID-19. Here’s what we know so far.
What’s on the horizon beyond infection prevention and supportive care for COVID-19? Read about some of the drugs in clinical trials.
Patients visiting their physicians are asking a lot of questions about COVID-19. Here are answers to ten most commonly asked questions from the Infectious Diseases team at DynaMed®.
COVID-19 represents the most recent example of health disparity among Black patients in America. This EBM Focus article discusses a study evaluating this inequity.
In April 2020, the DynaMed® EBM Focus team answered ten common clinical questions about COVID-19. Here is an updated list of questions physicians are asking now.
Patients with pre-existing conditions are at a higher risk for severe COVID-19. Read about considerations for certain high-risk patient populations during the pandemic.
A scary new facet of COVID-19 in children is starting to emerge. Here’s what we know about multisystem inflammatory syndrome in children (MIS-C).
High-quality randomized trials evaluating tocilizumab continue to show only modest effects in patients with severe COVID-19. Read about the latest trial in this EBM Focus article.